ARID1A and cancer: In addition, previous studies have suggested that ARID1A alterations may contribute to impaired MMR or mutation phenotypes in cancer patients and could cooperate with immune checkpoint blockade therapy.46–48 Consistent with these reports, our study revealed a positive effect of ARID1A mutation on the efficacy of sintilimab plus anlotinib.